Helene Aschmann, PhD
Postdoctoral Scholar
Medicine
School of Medicine

Education & Training

Show all (2) Hide

• PhD Epidemiology University of Zurich 05/2020
• MSc Medicinal and Industrial Pharmaceutical Sciences Swiss Federal Institute of Technology ETH Zürich 04/2015

Websites

Show all (1) Hide

• Posts on X LnAschmann (X.com)

Grants and Projects

Show all (1) Hide

• Informing patient-centered care through quantitative benefit-harm assessment in latent tuberculosis, Swiss National Science Foundation, 2021-2022

Publications (18)

Top publication keywords:
Multiple Chronic ConditionsRisk AssessmentDecision MakingHydroxymethylglutaryl-CoA Reductase InhibitorsPatient PreferencePatient ParticipationBlood PressureEarly Detection of CancerPatient-Centered CareLipid BilayersPrimary PreventionHypertensionDyslipidemiasStakeholder ParticipationPharmacokinetics

• A Data-Driven Simulation of the Exposure Notification Cascade for Digital Contact Tracing of SARS-CoV-2 in Zurich, Switzerland.
  JAMA network open 2021 Menges D, Aschmann HE, Moser A, Althaus CL, von Wyl V
• Assessment of Patient-Preferred Language to Achieve Goal-Aligned Deprescribing in Older Adults.
  JAMA network open 2021 Green AR, Aschmann H, Boyd CM, Schoenborn N
• [Cancer Screening - Prerequesites for a Successful and Meaningful Screening Program].
  Therapeutische Umschau. Revue therapeutique 2021 Aschmann HE, Puhan MA
• Global variation of risk thresholds for initiating statins for primary prevention of cardiovascular disease: a benefit-harm balance modelling study.
  BMC cardiovascular disorders 2020 Yebyo HG, Zappacosta S, Aschmann HE, Haile SR, Puhan MA
• Benefit-harm balance of fingolimod in patients with MS: A modelling study based on FREEDOMS.
  Multiple sclerosis and related disorders 2020 Spanu A, Aschmann HE, Kesselring J, Puhan MA

Show all (13 more) Hide

• Informing Patient-Centered Care Through Stakeholder Engagement and Highly Stratified Quantitative Benefit-Harm Assessments.
  Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research 2020 Aschmann HE, Boyd CM, Robbins CW, Chan WV, Mularski RA, Bennett WL, Sheehan OC, Wilson RF, Bayliss EA, Leff B, Armacost K, Glover C, Maslow K, Mintz S, Puhan MA
• Outcome preferences of older people with multiple chronic conditions and hypertension: a cross-sectional survey using best-worst scaling.
  Health and quality of life outcomes 2019 Aschmann HE, Puhan MA, Robbins CW, Bayliss EA, Chan WV, Mularski RA, Wilson RF, Bennett WL, Sheehan OC, Yu T, Yebyo HG, Leff B, Tabano H, Armacost K, Glover C, Maslow K, Mintz S, Boyd CM
• Net benefit of statins for primary prevention of cardiovascular disease in people 75 years or older: a benefit-harm balance modeling study.
  Therapeutic advances in chronic disease 2019 Yebyo HG, Aschmann HE, Menges D, Boyd CM, Puhan MA
• Balance of benefits and harms of different blood pressure targets in people with multiple chronic conditions: a quantitative benefit-harm assessment.
  BMJ open 2019 Aschmann HE, Boyd CM, Robbins CW, Mularski RA, Chan WV, Sheehan OC, Wilson RF, Bennett WL, Bayliss EA, Yu T, Leff B, Armacost K, Glover C, Maslow K, Mintz S, Puhan MA
• Statins for Primary Prevention of Cardiovascular Disease.
  Annals of internal medicine 2019 Yebyo HG, Aschmann HE, Puhan MA
• A benefit-harm analysis of adding basal insulin vs. sulfonylurea to metformin to manage type II diabetes mellitus in people with multiple chronic conditions.
  Journal of clinical epidemiology 2019 Bennett WL, Aschmann HE, Puhan MA, Robbins CW, Bayliss EA, Wilson R, Mularski RA, Chan WV, Leff B, Sheehan O, Glover C, Maslow K, Armacost K, Mintz S, Boyd CM
• Comparative effectiveness and safety of statins as a class and of specific statins for primary prevention of cardiovascular disease: A systematic review, meta-analysis, and network meta-analysis of randomized trials with 94,283 participants.
  American heart journal 2019 Yebyo HG, Aschmann HE, Kaufmann M, Puhan MA
• Finding the Balance Between Benefits and Harms When Using Statins for Primary Prevention of Cardiovascular Disease: A Modeling Study.
  Annals of internal medicine 2018 Yebyo HG, Aschmann HE, Puhan MA
• Should statin guidelines consider patient preferences? Eliciting preferences of benefit and harm outcomes of statins for primary prevention of cardiovascular disease in the sub-Saharan African and European contexts.
  BMC cardiovascular disorders 2018 Yebyo HG, Aschmann HE, Yu T, Puhan MA
• Kinetics of lipid bilayer permeation of a series of ionisable drugs and their correlation with human transporter-independent intestinal permeability.
  European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences 2017 Hermann KF, Neuhaus CS, Micallef V, Wagner B, Hatibovic M, Aschmann HE, Paech F, Alvarez-Sanchez R, Krämer SD, Belli S
• A Comparative Analysis of Drug-Induced Hepatotoxicity in Clinically Relevant Situations.
  PLoS computational biology 2017 Thiel C, Cordes H, Fabbri L, Aschmann HE, Baier V, Smit I, Atkinson F, Blank LM, Kuepfer L
• A Physiologically Based Pharmacokinetic Model of Isoniazid and Its Application in Individualizing Tuberculosis Chemotherapy.
  Antimicrobial agents and chemotherapy 2016 Cordes H, Thiel C, Aschmann HE, Baier V, Blank LM, Kuepfer L
• When barriers ignore the "rule-of-five".
  Advanced drug delivery reviews 2016 Krämer SD, Aschmann HE, Hatibovic M, Hermann KF, Neuhaus CS, Brunner C, Belli S